Xelox After Gastric Surgery Significantly Improves Disease-Free Survival

Oncology & Biotech News
Published: Wednesday, Aug 03, 2011
Yung-Jue Bang, MD

Yung-Jue Bang, MD

Patients with operable gastric cancer had significant improvement in disease-free survival (DFS) with adjuvant capecitabine plus oxaliplatin (Xelox) following definitive surgery, according to results of a large international trial.

Table. Stratified 3-Year Disease-Free Survival Rates

Category
Subgroup No.
Patients
HR Estimate
 
All
All
1035
0.58
 
Stage of disease

 

 
Stage II

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x